Samumed Biosplice SM04554 Wnt pathway modulator illustration showing hair follicle molecular mechanism for androgenetic alopecia treatment — SM04554 activates Wnt pathway to stimulate hair follicle growth and cycling.

Samumed / Biosplice Therapeutics

United StatesFounded 2008

About Samumed / Biosplice Therapeutics

Biotechnology company developing SM04554, a topical Wnt pathway modulator for androgenetic alopecia. The Wnt signaling pathway plays a role in hair follicle development and cycling. Phase 2 clinical trials showed dose-dependent increases in hair count. The company rebranded from Samumed to Biosplice in 2021.

Product Categories

BiotechPharmaceuticals

← All manufacturers